Table 1 Clinical and pathological characteristics of the five independent HNSCC cohortsa
Characteristics | TCGA cohort (n = 566) | Leipzig cohort (n = 270) | FHCRC cohort (n = 97) | MDACC cohort (n = 74) | Greece cohort (n = 109) |
|---|---|---|---|---|---|
Age | |||||
 ≥ 60 | 316 (55.83%) | 117 (43.33%) | 47 (48.45%) | 37 (50.00%) | 74 (67.89%) |
 < 60 | 249 (43.99%) | 153 (56.67%) | 50 (51.55%) | 37 (50.00%) | 35 (32.11%) |
 Unknown | 1 (0.18%) | 0 | 0 | 0 | 0 |
Sex | |||||
 Male | 415 (73.32%) | 223 (82.59%) | 66 (68.04%) | 58 (78.38%) | 104 (95.41%) |
 Female | 151 (26.68%) | 47 (17.41%) | 31 (31.96%) | 16 (21.62%) | 5 (4.59%) |
Smoking | |||||
 Yes | 423 (74.73%) | 222 (82.22%) | NA | 59 (79.73%) | 108 (99.08%) |
 No | 128 (22.61%) | 48 (17.78%) | NA | 15 (20.27%) | 1 (0.92%) |
 Unknown | 15 (2.65%) | 0 | NA | 0 | 0 |
Alcohol | |||||
 Yes | 371 (65.55%) | 239 (88.52%) | NA | NA | 58 (53.21%) |
 No | 182 (32.16%) | 31 (11.48%) | NA | NA | 51 (46.79%) |
 Unknown | 13 (2.3%) | 0 | NA | NA | 0 |
Tumor site | |||||
 Oral cavity | 346 (61.13%) | 83 (30.74%) | 97 (100%) | 71 (95.95%) | 0 |
 Oropharynx | 82 (14.49%) | 102 (37.78%) | 0 | 3 (4.05%) | 0 |
 Larynx | 128 (22.61%) | 48 (17.78%) | 0 | 0 | 109 (100%) |
 Hypopharynx | 10 (1.77%) | 33 (12.22%) | 0 | 0 | 0 |
 Unknown | 0 | 4 (1.48%) | 0 | 0 | 0 |
T classification | |||||
 T1-T2 | 218 (38.52%) | 115 (42.59%) | NA | 30 (40.54%) | NA |
 T3-T4 | 344 (60.78%) | 155 (57.41%) | NA | 44 (59.46%) | NA |
 Unknown | 4 (0.71%) | 0 | NA | 0 | NA |
N classification | |||||
 Negative | 295 (52.12%) | 94 (34.81%) | NA | 42 (56.76%) | NA |
 Positive | 267 (47.17%) | 176 (65.19%) | NA | 32 (43.24%) | NA |
 Unknown | 4 (0.71%) | 0 | NA | 0 | NA |
Stage | |||||
 I-II | 135 (23.85%) | 55 (20.37%) | 41 (42.27%) | 19 (25.68%) | 30 (27.52%) |
 III-IV | 417 (73.67%) | 215 (79.63%) | 56 (57.73%) | 55 (74.32%) | 79 (72.48%) |
 Unknown | 14 (2.47%) | 0 | 0 | 0 | 0 |
HPV status | |||||
 Positive | 68 (12.01%) | 60 (22.22%) | 0 | NA | NA |
 Negative | 274 (48.41%) | 209 (77.41%) | 97 (100%) | NA | NA |
 Unknown | 224 (39.58%) | 1 (0.37%) | 0 | NA | NA |
Radiotherapy | |||||
 Yes | 304 (53.71%) | NA | NA | 47 (63.51%) | 54 (49.54%) |
 No | 171 (30.21%) | NA | NA | 26 (35.14%) | 43 (39.45%) |
 Unknown | 91 (16.08%) | NA | NA | 1 (1.35%) | 12 (11.01%) |
Treatment | |||||
 Unimodal | 188 (33.22%) | 78 (28.89%) | 43 (44.33%) | 25 (33.78%) | 43 (39.45%) |
 Multimodal | 278 (49.12%) | 189 (70.00%) | 53 (54.64%) | 48 (64.87%) | 54 (49.54%) |
 Palliative | 1 (0.17%) | 3 (1.11%) | 0 | 0 | 0 |
 Unknown | 99 (17.49%) | 0 | 1 (1.03%) | 1 (1.35%) | 12 (11.01%) |
CSC gene expression signature | |||||
 CSC-HR subgroup | 285 (50.35%) | 122 (45.19%) | 38 (39.18%) | 47 (63.51%) | 57 (52.29%) |
 CSC-LR subgroup | 281 (49.65%) | 148 (54.81%) | 59 (60.82%) | 27 (36.49%) | 52 (47.71%) |